A 74-year-old man with an unremarkable medical history noted a progressive gait disorder in the months prior to admission. His wife recalled increased sleepiness and loss of initiative. After having ...
With amyloid immunotherapy in clinical use, scientists need to find better ways to identify the patients most at risk of developing ARIA (see part 16 of this series). One of the biggest danger signs, ...
Bright spots called white-matter hyperintensities (WMHs) often appear on MRI scans of people with familial or sporadic Alzheimer’s disease, and they tend to intensify as the disease progresses. Some ...
ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...
A common type of brain bleed in older adults, known as subdural hemorrhage, is associated with the presence of amyloid deposits in cerebral blood vessels, according to a study led by researchers at ...
Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the midstage study has been tied to one death. The interim data come from ...
CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback